Quick Order Cart

Cat. No. ARG43730

ATAD1 Knockout Hela Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Uterus (cervix)

  • Disease:

    Adenocarcinoma

The ATAD1 Knockout Hela Cell Line is a CRISPR/Cas9-edited human cervical adenocarcinoma cell line with targeted disruption of the ATAD1 gene. ATAD1 encodes an AAA+ ATPase that disassembles mitofusin complexes (MFN1/MFN2) on mitochondria and extracts AMPA receptors (GRIA1/GRIA2) at synapses, regulating mitochondrial dynamics and synaptic transmission. This knockout model, in the widely used Hela background, enables mechanistic studies of mitochondrial quality control, mitophagy, and receptor trafficking. Applications include mitochondrial morphology assays, Seahorse metabolic analysis, co-immunoprecipitation for ATAD1-interacting partners, and drug screening for modulators of mitophagy. For additional details, contact Ascent Research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HeLa

    Sex of Donor

    Female

    Age

    31 years

    Gene Name

    ATAD1

    Gene Identifier

    NCBI Gene ID 84896

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ATAD1 Knockout Hela Cell Line is a CRISPR/Cas9-edited human cell line with targeted disruption of ATAD1 in the Hela cervical adenocarcinoma background. This stable knockout model enables loss-of-function studies of ATAD1, a key regulator of mitochondrial dynamics and synaptic receptor trafficking, without endogenous gene interference.

Hela cells are a widely used human epithelial cell line derived from cervical adenocarcinoma. They are HPV18-positive, resulting in inactivation of p53 and Rb by viral oncoproteins E6 and E7, which facilitates uncontrolled proliferation and provides a well-characterized genetic context. This background is advantageous for investigating mitochondrial function and protein trafficking pathways independent of these tumor suppressors.

ATAD1 encodes an AAA+ ATPase that disassembles mitofusin complexes (MFN1, MFN2) on the mitochondrial outer membrane to prevent hyperfusion and maintains organelle morphology, also facilitating mitophagy. At synapses, it extracts AMPA-type glutamate receptors (GRIA1/GRIA2) from the plasma membrane for lysosomal degradation, regulating excitatory neurotransmission. ATAD1 activity is influenced by cellular energy status, calcium signaling, and kinase cascades. It interacts directly with MFN1, MFN2, GRIA1, GRIA2, and proteasomal components, linking mitochondrial dynamics with synaptic plasticity. Key pathway effectors include OPA1, DRP1, PINK1, and Parkin.

In Hela cells, ATAD1 knockout provides a tractable system to study mitochondrial hyperfusion, cristae disorganization, and impaired mitophagic clearance. Although non-neuronal, these cells express the core mitochondrial fission-fusion machinery, making them suitable for dissecting the mitochondrial functions of ATAD1 without synaptic complexity. The knockout line enables complementation with wild-type or mutant ATAD1 to explore structure-function relationships and allows investigation of metabolic consequences in a cancerous background.

This knockout line supports diverse applications, including MitoTracker staining and live-cell imaging to assess mitochondrial morphology, Seahorse metabolic assays for respiratory function, and co-immunoprecipitation/western blotting to analyze MFN1/MFN2 interactions. In neuronal co-culture systems, it can be used to examine AMPA receptor trafficking via surface biotinylation and electrophysiology. It is also an excellent platform for drug screening to identify mitophagy modulators. For further information or customized requests, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)